Frede N. Donskov
Impact in
- Pulmonary and Respiratory Medicine top 0.05%
- Renal cell carcinoma treatment
- Ferroptosis and cancer prognosis
- Oncology top 0.1%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
Papers in
-
- Renal cell carcinoma treatment 131
- Oncology 39
- Cancer Immunotherapy and Biomarkers 15
- Pancreatic and Hepatic Oncology Research 10
- Co-authors
- Hans von der Maase (13 shared papers)Toni K. Choueiri (62 shared papers)Brian I. Rini (42 shared papers)Georg Arnold Bjarnason (39 shared papers)Daniel Y.C. Heng (42 shared papers)Lori Anne Wood (34 shared papers)Christian Kollmannsberger (30 shared papers)Ulka N. Vaishampayan (24 shared papers)
- Journals
- Annals of Oncology (22 papers)European Urology (20 papers)Clinical Genitourinary Cancer (15 papers)European Journal of Cancer (10 papers)Acta Oncologica (9 papers)
- Partner nations
- DenmarkUnited StatesCanada
In The Last Decade
Frede N. Donskov
180 papers receiving 22.3k citations
Frede N. Donskov's Hit Papers
Peers
Comparison fields: 5 of 111
- Pulmonary and Respiratory Medicine 13.0k
- Oncology 9.0k
- Cancer Research 3.7k
- Immunology 3.0k
- Molecular Biology 5.0k
Countries citing papers authored by Frede N. Donskov
This map shows the geographic impact of Frede N. Donskov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frede N. Donskov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frede N. Donskov more than expected).
Fields of papers citing papers by Frede N. Donskov
This network shows the impact of papers produced by Frede N. Donskov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frede N. Donskov. The network helps show where Frede N. Donskov may publish in the future.
Co-authors
The 25 scholars most cited alongside Frede N. Donskov, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 184 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma Hit paper breakdown → | 2015 | 4815 |
| 2 | Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma Hit paper breakdown → | 2018 | 3643 |
| 3 | Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma Hit paper breakdown → | 2015 | 1004 |
| 4 | External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study Hit paper breakdown → | 2013 | 827 |
| 5 | Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial Hit paper breakdown → | 2019 | 817 |
| 6 | Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial Hit paper breakdown → | 2016 | 778 |
| 7 | Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial Hit paper breakdown → | 2019 | 643 |
| 8 | Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy Hit paper breakdown → | 2016 | 592 |
| 9 | Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial Hit paper breakdown → | 2020 | 410 |
| 10 | 2009 | 393 | |
| 11 | Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium Hit paper breakdown → | 2014 | 359 |
| 12 | The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study Hit paper breakdown → | 2015 | 320 |
| 13 | 2017 | 299 | |
| 14 | 2014 | 290 | |
| 15 | 2006 | 261 | |
| 16 | 2013 | 248 | |
| 17 | 2020 | 247 | |
| 18 | 2011 | 232 | |
| 19 | Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma Hit paper breakdown → | 2021 | 224 |
| 20 | 2013 | 214 |
About Frede N. Donskov
Frede N. Donskov is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Immunology and Molecular Biology, having authored 184 papers that have together received 22.7k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (131 papers), Renal and related cancers (25 papers), Cancer Genomics and Diagnostics (17 papers), Cancer Immunotherapy and Biomarkers (15 papers), Pancreatic and Hepatic Oncology Research (10 papers), Economic and Financial Impacts of Cancer (8 papers), Immune cells in cancer (8 papers) and Immune Cell Function and Interaction (6 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (13.0k citations), Oncology (9.0k citations), Cancer Research (3.7k citations), Immunology (3.0k citations) and Molecular Biology (5.0k citations). Frede N. Donskov has collaborated with scholars based in Denmark, United States and Canada. Frequent co-authors include Hans von der Maase, Toni K. Choueiri, Brian I. Rini, Georg Arnold Bjarnason, Daniel Y.C. Heng, Lori Anne Wood, Christian Kollmannsberger, Ulka N. Vaishampayan, Sun Young Rha and Neeraj Agarwal. Their work appears in journals such as Annals of Oncology, European Urology, Clinical Genitourinary Cancer, European Journal of Cancer and Acta Oncologica.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.